EE05244B1 - Quinazoline derivatives, drugs containing these compounds, their use and a process for their preparation - Google Patents

Quinazoline derivatives, drugs containing these compounds, their use and a process for their preparation

Info

Publication number
EE05244B1
EE05244B1 EEP200300300A EEP200300300A EE05244B1 EE 05244 B1 EE05244 B1 EE 05244B1 EE P200300300 A EEP200300300 A EE P200300300A EE P200300300 A EEP200300300 A EE P200300300A EE 05244 B1 EE05244 B1 EE 05244B1
Authority
EE
Estonia
Prior art keywords
compounds
preparation
quinazoline derivatives
drugs containing
drugs
Prior art date
Application number
EEP200300300A
Other languages
Estonian (et)
Inventor
Himmelsbach Frank
Langkopf Elke
Blech Stefan
Jung Birgit
Baum Anke
Solca Flavio
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7667887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05244(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of EE200300300A publication Critical patent/EE200300300A/en
Publication of EE05244B1 publication Critical patent/EE05244B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
EEP200300300A 2000-12-20 2001-12-12 Quinazoline derivatives, drugs containing these compounds, their use and a process for their preparation EE05244B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10063435A DE10063435A1 (en) 2000-12-20 2000-12-20 Chinazoline derivatives, pharmaceuticals containing these compounds, their use and process for their preparation
PCT/EP2001/014569 WO2002050043A1 (en) 2000-12-20 2001-12-12 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof

Publications (2)

Publication Number Publication Date
EE200300300A EE200300300A (en) 2003-10-15
EE05244B1 true EE05244B1 (en) 2009-12-15

Family

ID=7667887

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300300A EE05244B1 (en) 2000-12-20 2001-12-12 Quinazoline derivatives, drugs containing these compounds, their use and a process for their preparation

Country Status (40)

Country Link
EP (2) EP1345910B9 (en)
JP (1) JP3827641B2 (en)
KR (1) KR100852102B1 (en)
CN (1) CN1277822C (en)
AR (1) AR040524A1 (en)
AT (1) ATE430136T1 (en)
AU (2) AU2002219174B2 (en)
BE (1) BE2014C009I2 (en)
BG (1) BG66139B1 (en)
BR (1) BRPI0116266B8 (en)
CA (1) CA2432428C (en)
CY (2) CY1109290T1 (en)
CZ (1) CZ302721B6 (en)
DE (2) DE10063435A1 (en)
DK (1) DK1345910T3 (en)
EA (1) EA006317B1 (en)
EE (1) EE05244B1 (en)
ES (1) ES2326617T3 (en)
FR (1) FR14C0009I2 (en)
HK (1) HK1060571A1 (en)
HR (1) HRP20030504B1 (en)
HU (2) HU228874B1 (en)
IL (2) IL156277A0 (en)
LT (1) LTC1345910I2 (en)
LU (1) LU92370I2 (en)
ME (1) ME02777B (en)
MX (1) MXPA03005559A (en)
MY (1) MY136086A (en)
NO (3) NO325672B1 (en)
NZ (1) NZ526918A (en)
PL (1) PL214798B1 (en)
PT (1) PT1345910E (en)
RS (1) RS50860B (en)
SI (1) SI1345910T1 (en)
SK (1) SK287573B6 (en)
TW (1) TWI295992B (en)
UA (1) UA74614C2 (en)
UY (1) UY27078A1 (en)
WO (1) WO2002050043A1 (en)
ZA (1) ZA200304141B (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71976C2 (en) 1999-06-21 2005-01-17 Boehringer Ingelheim Pharma Bicyclic heterocycles and a medicament based thereon
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (en) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10221018A1 (en) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
PE20040945A1 (en) * 2003-02-05 2004-12-14 Warner Lambert Co PREPARATION OF SUBSTITUTED QUINAZOLINES
DE10307165A1 (en) * 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334226A1 (en) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (en) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Process for the preparation of aminocrotonyl compounds
UA85706C2 (en) * 2004-05-06 2009-02-25 Уорнер-Ламберт Компани Ллси 4-phenylaminoquinazolin-6-yl amides
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
WO2006081741A1 (en) * 2005-02-05 2006-08-10 Piaoyang Sun Quinazoline compounds or their medical salts and preparation and medical usage thereof
KR100832594B1 (en) * 2005-11-08 2008-05-27 한미약품 주식회사 Quinazoline derivatives as an multiplex inhibitor and method for the preparation thereof
DK1948180T3 (en) 2005-11-11 2013-05-27 Boehringer Ingelheim Int Combination treatment of cancer including EGFR / HER2 inhibitors
EP3173084B1 (en) * 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
US7960546B2 (en) * 2006-01-26 2011-06-14 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
ES2385613T3 (en) * 2006-09-18 2012-07-27 Boehringer Ingelheim International Gmbh Method to treat cancers that carry EGFR mutations
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
MX2009007610A (en) 2007-02-06 2009-07-24 Boehringer Ingelheim Int Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof.
WO2009098061A1 (en) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
PE20100252A1 (en) 2008-06-06 2010-04-12 Boehringer Ingelheim Int NEW SOLID PHARMACEUTICAL FORMULATIONS INCLUDING 4 - [(3-CHLORO-4-FLUOROPHENYL) AMINO DIMALEATE] -6 - {[4- (N, N-DIMETHYLAMINO) -1-OXO-2-BUTEN-1-IL] AMINO } -7 - ((S) -TETRAHIDROFURAN-3-ILOXI) -QUINAZOLINA
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
JP5539351B2 (en) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cyclohexyloxy-substituted heterocycles, medicaments containing these compounds, and methods for producing them
WO2010054285A2 (en) 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
JP2012515184A (en) 2009-01-14 2012-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング How to treat colorectal cancer
WO2010130757A1 (en) 2009-05-14 2010-11-18 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
WO2010130758A1 (en) * 2009-05-14 2010-11-18 Boehringer Ingelheim International Gmbh New combination therapy in treatment of cancer and fibrotic diseases
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US20130012465A1 (en) 2009-12-07 2013-01-10 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer
US8735409B2 (en) * 2009-12-21 2014-05-27 Qiang Zhang Quinazoline derivatives
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
EP2608792B1 (en) 2010-08-26 2017-10-11 Boehringer Ingelheim International GmbH Methods of administering an egfr inhibitor
EP2643314B1 (en) * 2010-11-25 2016-07-13 ratiopharm GmbH Novel salts and polymorphic forms of afatinib
KR20200003933A (en) 2011-03-04 2020-01-10 뉴젠 세러퓨틱스 인코포레이티드 Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (en) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
CN102838590B (en) * 2011-06-21 2014-07-09 苏州迈泰生物技术有限公司 Amino quinazoline derivative and application thereof in preparation of antineoplastic drugs
EP2753616A1 (en) 2011-10-06 2014-07-16 Ratiopharm GmbH Crystalline forms of afatinib di-maleate
CN103073539B (en) * 2011-10-26 2016-05-11 齐鲁制药有限公司 4-(substituted benzene amino) quinazoline derivant and preparation method thereof, pharmaceutical composition and purposes
CN104080774B (en) 2012-01-17 2017-02-22 安斯泰来制药株式会社 Pyrazine carboxamide compound
CN103772380A (en) * 2012-10-23 2014-05-07 杨子娇 Type of compounds for treating narrow chamber angle and use of compounds
US20150368230A1 (en) 2013-02-01 2015-12-24 Boehringer Ingelheim International Gmbh Radiolabeled quinazoline derivatives
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (en) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Therapeutic uses of empagliflozin.
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
SI2986304T1 (en) 2013-04-18 2022-04-29 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN103254183B (en) * 2013-05-10 2015-11-11 苏州明锐医药科技有限公司 Ah method is for the preparation method of Buddhist nun
WO2014180271A1 (en) * 2013-05-10 2014-11-13 苏州明锐医药科技有限公司 Method for preparing afatinib and intermediate thereof
CN103254182A (en) * 2013-05-10 2013-08-21 苏州明锐医药科技有限公司 Method for preparing Afatinib
WO2014183560A1 (en) * 2013-05-16 2014-11-20 苏州明锐医药科技有限公司 Afatinib and preparation method of intermediate thereof
CN103242303B (en) * 2013-05-16 2015-03-25 苏州明锐医药科技有限公司 Afatinib preparation method
CN104513229A (en) 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 Quinazoline derivatives and preparation method thereof
CN103755688B (en) * 2013-12-24 2015-11-18 江苏奥赛康药业股份有限公司 A kind of Ah method is for the preparation method of Buddhist nun's compound
US9242965B2 (en) * 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
EA031059B1 (en) 2014-01-02 2018-11-30 Тева Фармасьютикалз Интернэшнл Гмбх Crystalline form alpha of afatinib di-maleate
CN105315263B (en) * 2014-07-30 2018-11-27 正大天晴药业集团股份有限公司 The synthetic method of afatinib intermediate
EP3023421A1 (en) 2014-11-21 2016-05-25 Sandoz Ag Crystalline forms of afatinib dimaleate
CN105801568B (en) 2015-01-15 2019-07-30 杭州普晒医药科技有限公司 One maleate crystal form of Afatinib and preparation method thereof and pharmaceutical composition
US10231973B2 (en) 2015-03-20 2019-03-19 Chai Tai Tianqing Pharmaceutical Group Co., Ltd. Salts of quinazoline derivative and method for preparing the same
CN105175400B (en) * 2015-09-29 2018-04-10 河北神威药业有限公司 A kind of preparation method of afatinib intermediate
WO2017141271A1 (en) * 2016-02-17 2017-08-24 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical composition of afatinib
CN106442793B (en) * 2016-10-21 2019-05-24 河北神威药业有限公司 A kind of detection method of the intermediate for preparing Afatinib and its enantiomter
TWI808958B (en) 2017-01-25 2023-07-21 美商特普醫葯公司 Combination therapy involving diaryl macrocyclic compounds
JP2021506974A (en) * 2017-12-18 2021-02-22 スターングリーン、インク. Pyrimidine compounds useful as tyrosine kinase inhibitors
CN110437163A (en) * 2018-05-03 2019-11-12 斯特恩格林公司 Pyrimidines as tyrosine kinase inhibitor
CN113382986A (en) 2018-09-25 2021-09-10 黑钻治疗公司 Tyrosine kinase inhibitor compositions, methods of making and methods of using the same
CN109265449B (en) * 2018-11-07 2021-11-23 沈阳工业大学 EGFR and HER2 double-target tyrosine kinase inhibitor and preparation method and application thereof
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN109824657A (en) * 2019-03-26 2019-05-31 石药集团中奇制药技术(石家庄)有限公司 Two maleic acid Afatinib novel crystal forms of one kind and its preparation method and application
CN110590682A (en) * 2019-10-14 2019-12-20 重庆医科大学 Method for preparing afatinib impurity and prepared impurity
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
KR20220130190A (en) 2020-01-20 2022-09-26 아스트라제네카 아베 Epidermal growth factor receptor tyrosine kinase inhibitor for cancer treatment
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TWI847289B (en) * 2021-09-30 2024-07-01 大陸商北京賽特明強醫藥科技有限公司 Quinazoline compounds, compositions and applications thereof
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126351A0 (en) * 1996-04-12 1999-05-09 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
DE19911366A1 (en) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases
DE19908567A1 (en) * 1999-02-27 2000-08-31 Boehringer Ingelheim Pharma New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases
AU3281600A (en) * 1999-02-27 2000-09-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
DE19911509A1 (en) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
UA71976C2 (en) * 1999-06-21 2005-01-17 Boehringer Ingelheim Pharma Bicyclic heterocycles and a medicament based thereon
ES2280375T3 (en) * 2000-04-08 2007-09-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG BICYCLE HETEROCICLES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURE FOR PREPARATION.

Also Published As

Publication number Publication date
EP1345910A1 (en) 2003-09-24
EE200300300A (en) 2003-10-15
CN1481370A (en) 2004-03-10
CY1109290T1 (en) 2014-07-02
HRP20030504B1 (en) 2011-09-30
PL214798B1 (en) 2013-09-30
HUP0301852A2 (en) 2003-09-29
EP1345910B1 (en) 2009-04-29
DE50114874D1 (en) 2009-06-10
AU1917402A (en) 2002-07-01
UA74614C2 (en) 2006-01-16
ME02777B (en) 2011-10-10
NO20032726D0 (en) 2003-06-16
NO2014003I2 (en) 2015-10-19
MY136086A (en) 2008-08-29
NO2014003I1 (en) 2014-06-02
HK1060571A1 (en) 2004-08-13
EA200300671A1 (en) 2004-06-24
UY27078A1 (en) 2002-07-31
HUS1400005I1 (en) 2017-08-28
NO325672B1 (en) 2008-07-07
EP1345910B9 (en) 2014-06-04
MEP59508A (en) 2011-05-10
HUP0301852A3 (en) 2008-03-28
EA006317B1 (en) 2005-10-27
AR040524A1 (en) 2005-04-13
LU92370I2 (en) 2014-03-31
CN1277822C (en) 2006-10-04
BG66139B1 (en) 2011-07-29
TWI295992B (en) 2008-04-21
YU49603A (en) 2006-05-25
KR20030071787A (en) 2003-09-06
ATE430136T1 (en) 2009-05-15
BE2014C009I2 (en) 2021-02-04
PL361798A1 (en) 2004-10-04
AU2002219174B2 (en) 2007-09-06
EP2112140A1 (en) 2009-10-28
CZ20031930A3 (en) 2003-10-15
HRP20030504A2 (en) 2005-06-30
LU92370I9 (en) 2019-01-17
KR100852102B1 (en) 2008-08-13
CA2432428A1 (en) 2002-06-27
DK1345910T3 (en) 2009-07-20
MXPA03005559A (en) 2004-10-14
CA2432428C (en) 2009-09-01
ZA200304141B (en) 2004-04-15
RS50860B (en) 2010-08-31
SK7712003A3 (en) 2003-10-07
ES2326617T9 (en) 2014-09-10
CY2014008I2 (en) 2015-12-09
IL156277A (en) 2009-12-24
FR14C0009I1 (en) 2014-03-07
LTPA2014005I1 (en) 2022-05-25
PT1345910E (en) 2009-07-14
HU228874B1 (en) 2013-06-28
NO20032726L (en) 2003-06-16
DE10063435A1 (en) 2002-07-04
CY2014008I1 (en) 2014-07-02
JP2004516283A (en) 2004-06-03
BG107929A (en) 2005-01-31
WO2002050043A1 (en) 2002-06-27
SI1345910T1 (en) 2009-08-31
NZ526918A (en) 2006-11-30
FR14C0009I2 (en) 2014-11-14
BR0116266A (en) 2004-02-17
SK287573B6 (en) 2011-03-04
LTC1345910I2 (en) 2022-06-10
ES2326617T3 (en) 2009-10-16
BRPI0116266B8 (en) 2021-07-27
CZ302721B6 (en) 2011-09-21
BRPI0116266B1 (en) 2017-10-31
JP3827641B2 (en) 2006-09-27
IL156277A0 (en) 2004-01-04
NO2022028I1 (en) 2022-07-01

Similar Documents

Publication Publication Date Title
EE05244B1 (en) Quinazoline derivatives, drugs containing these compounds, their use and a process for their preparation
EE05269B1 (en) Bicyclic heterocyclic compounds, drugs containing these compounds, their use and methods for their preparation
EE9800277A (en) 4-Aminopyrimidine derivatives, drugs containing these compounds, their use and a process for their preparation
EE04748B1 (en) Bicyclic heterocyclic compounds, drugs containing these compounds, their use and methods for their preparation
NO20032733L (en) Diphenyllazetidinone derivatives, process for their preparation, drugs containing these compounds and their use
EE05240B1 (en) Ortho and meta-substituted bisar compounds, their use and pharmaceutical preparations containing them
NO20024175D0 (en) Acetidine derivatives, their preparation and pharmaceutical compounds containing the same
NO20032735L (en) Diphenyllazetidinone derivatives, process for their preparation, drugs containing these compounds and their use
EE05134B1 (en) Adamantane derivatives, a process for their preparation, pharmaceutical compositions containing them and their use in therapy
EE200200369A (en) Substituted piperidines, drugs containing these compounds and methods for their preparation
EE05183B1 (en) Azabitic compounds, their preparation and use as pharmaceuticals, and the pharmaceutical composition containing them
NO20021719L (en) 6-position substituted indolines, preparation and use thereof as a drug
EE200200149A (en) Quinazoline compounds and pharmaceutical compositions containing them
NO20011216L (en) Acetidine derivatives, their preparation and medicaments containing the compounds
EE200100376A (en) Aromatic heterocyclic compounds, their use and methods for their preparation
EE200300327A (en) Urea derivatives, processes for their preparation, use and pharmaceutical composition
EE200200409A (en) 1,3-Dihydro-2H-indol-2-one derivatives, process for their preparation and pharmaceutical compositions containing them
EE04464B1 (en) Indalyl-substituted benzenecarboxamides, process for their preparation, use and pharmaceutical compositions
AU2001284021A1 (en) Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof
EE04721B1 (en) Phenylxanthine derivatives, processes for their preparation and use
EE200300254A (en) Heterocyclic Compounds having antibacterial activity, process for their preparation, and pharmaceutical compositions containing them
EE200200041A (en) Carboxylic acid amides, medicaments containing these compounds, their use and preparation
EE200300245A (en) Benzothiophene derivatives, process for their preparation and use
ATA59499A (en) PHARMACEUTICAL PREPARATION CONTAINING TOLPERISON FOR ORAL ADMINISTRATION
EE200100422A (en) Epothilone derivatives, process for their preparation and pharmaceutical use

Legal Events

Date Code Title Description
HB1A Correction of owner name or address
KB4A Valid patent at the end of a year

Effective date: 20101231

AA1Y Spc filed

Free format text: PRODUCT NAME: AFATINIIB;REG NO/DATE: K(2013)6342 (LOPLIK) 25.09.2013

Spc suppl protection certif: C20140003

Filing date: 20140213

FG1Y Spc granted

Free format text: PRODUCT NAME: AFATINIIB;REG NO/DATE: K(2013)6342 (LOPLIK) 25.09.2013

Spc suppl protection certif: C20140003 00098

Filing date: 20140213

Extension date: 20261212

SPCT Party data change related to a supplementary protection certificate

Spc suppl protection certif: 00098

SPCZ Extension of supplementary protection certificate: granted [paediatric extension]

Free format text: PRODUCT: AFATINIIB

Spc suppl protection certif: C20140003

Extension date: 20270612